SUZHOU, CHINA

CStone Announces the First-in-Class Registrational Clinical Trial of Sugemalimab Met its Primary Endpoint in Stage III NSCLC and Plans to Submit a New Drug Application

– Sugemalimab becomes the world’s first anti-PD-1/PD-L1 monoclonal antibody to successfully improve progression-free survival (PFS) in patients with stage III non-small-cell lung cancer (NSCLC) without disease progression after concurrent or sequential chemoradiotherapy – Sugemalimab is also the world’s first anti-PD-1/PD-L1 monoclonal antibody covering both locally advanced/unresectable (stage III) and metastatic (stage…

thaipr.net

28 พ.ค. 64

GCLSI Successfully Raises CNY2.5 billion ($US386 million) through Private Placement Share Offering

GCL System Integration Technology Co. Ltd (“GCLSI” or “the Company”) (Shenzhen:002506), a leading photovoltaics (PV) company in China, announced on January 21 that it successfully raised 2.5 billion yuan ($US386 million) through a private placement offering, which will accelerate the implementation of the Company’s “dual-core business(photovoltaic and semiconductor)” strategy. In a report on non-public…

thaipr.net

27 ม.ค. 64

GCLSI Supplies 64MW Solar Modules to Two Large PV Plants in Japan

GCL System Integration (“GCLSI” or “the Company”), a world-leading, one-stop and integrated energy system provider, has announced its cooperation with a leading Japanese solar energy project construction company to build two utility-scale solar power stations in Japan. Both solar power stations are currently under construction and they are expected to connect to the grid at […]

thaipr.net

30 พ.ย. 63
1 2 3 4

Copyright © 2025 Dataxet Limited (บริษัท ดาต้าเซ็ต จำกัด). All Rights Reserved.